Brief: Biomerieux Sees 2024 Sales Growth Of Between +6% And +8%

Biomerieux SA

14/03/2024 06:17

March 14 (Reuters) - Biomerieux SA  BIOX.PA :
    * Q4 2023 TOTAL SALES OF EUR 1 BILLION, UP 3.1% ORGANIC ON A
HIGH
TRIPLE DEMIC COMPARISON BASIS IN Q4 2022
    * FY CONTRIBUTIVE OPERATING INCOME REACHED €610 MILLION
(16.6% OF
SALES), UP 2% AT CONSTANT EXCHANGE RATE AND SCOPE
    * OUTLOOK 2024:  CONTRIBUTIVE OPERATING INCOME BEFORE
NON-RECURRING ITEMS IS EXPECTED TO GROW AT LEAST BY +10% AT 
CONSTANT EXCHANGE RATES
    * 2024 GUIDANCE:  SALES GROWTH BETWEEN +6% AND +8% AT
CONSTANT
EXCHANGE RATES AND SCOPE OF CONSOLIDATION
    * OUTLOOK 2024:  IMPROVEMENT OF THE OPERATING MARGIN OF AT
LEAST
+50BPS AT CONSTANT  EXCHANGE RATE.
    * OUTLOOK 2024: NEGATIVE FOREIGN EXCHANGE IMPACT IN THE
RANGE OF
-€50 MILLION VERSUS 2023 IS  EXPECTED IN 2024
    * FY CONSOLIDATED SALES AMOUNTED TO €3,675 MILLION IN 2023,
UP
6.6% FROM €3,589 MILLION IN THE PRIOR-YEAR PERIOD
    * NET INCOME, GROUP SHARE REACHED EUR 358 MILLION IN 2023
VERSUS
EUR 452 MILLION IN 2022
    * BOARD RECOMMENDS DIVIDEND OF €0.85 PER SHARE, REPRESENTING
A
PAYOUT RATIO OF 28% OF NET INCOME

Source text for Eikon:  urn:newsml:reuters.com:*:nNDL6myC0Q
Further company coverage:  BIOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))